Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

50 results about "Methylamine hydrochloride" patented technology

Methylamine Hydrochloride (DEA List I Chemical) M1242 | 593-51-1 Methylamine Hydrochloride (DEA List I Chemical) from Spectrum Chemical is a colorless organic solid that has an odor similar to that of fish and is used as an essential part for the synthesis of a wide variety of commercial compounds suc.

Method for preparing naftifine hydrochloride

The invention discloses a preparation method of naftifine hydrochloride, which uses N-methyl-1-naphthyl methylamine hydrochloride as raw material, to directly participate reaction without alkalization free purification, uses organic ether solvent as reaction solvent, in the presence of alkali metal carbonate and catalyst, at suitable temperature, to generate crude naftifine hydrochloride via condensation reaction, and feeds acetic ester saturated solution of hydrochloride to generate hydrochlorate, and obtains high-purity naftifine hydrochloride product via recrystallization. The invention completes alkalization free purification, and condensation reaction in one device, with simple operation, high yield, low foreign material content, low cost, and industrialization support, which is better than previous synthesis method.
Owner:TIANJIN WEIJIE PHARMA

Method for synthesizing [<2>H3]-1-methylamino-2-phenylpropane

The invention discloses a method for synthesizing [<2>H3]-1-methylamino-2-phenylpropane. The method is characterized by comprising the following steps: (1) subjecting phenylacetone, deuterated methylamine and tetraalkyl titanate or phenylacetone, deuterated methylamine, tetraalkyl titanate and an acid binding agent or phenylacetone, deuterated methylamine hydrochloride and tetraalkyl titanate to areaction, so as to obtain a first intermediate; (2) subjecting the first intermediate obtained in the step (1) and a reduction reagent to a reaction; (3) adding ammonia water into the step (2) for aquenching reaction, carrying out suction filtration to remove precipitates, carrying out precipitation with an organic solvent, merging liquid, and carrying out extraction and knockout to collect an organic phase, thereby obtaining the [<2>H3]-1-methylamino-2-phenylpropane. The method has the advantages that the synthesis route is short, the operation is simple and safe, the reaction time is short, and the yield exceeds 50%. Through further purification, both the purity and deuterated rate of the [<2>H3]-1-methylamino-2-phenylpropane can reach 99.5% or more, and thus, the [<2>H3]-1-methylamino-2-phenylpropane completely can serve as a deuterated internal reference substance for a mass-spectrum internal reference quantitative analysis method.
Owner:INST OF FORENSIC SCI OF MIN OF PUBLIC SECURITY

Temozolomide intermediate compound

The invention belongs to the technical field of medicine synthesis, and particularly relates to a temozolomide intermediate compound. According to the preparation method, 5-amino-1H-imidazole-4-nitrile is taken as an initial raw material and reacts with N, N '-carbonyldiimidazole, and the new temozolomide intermediate 5-amino-1-(1H-imidazole-1-carbonyl)-1H-imidazole-4-nitrile is obtained. Meanwhile, the invention provides a method for preparing temozolomide by using the novel intermediate compound. The method comprises the following steps: reacting 5-amino-1-(1H-imidazole-1-carbonyl)-1H-imidazole-4-nitrile with methylamine hydrochloride, diazotizing the obtained product, cyclizing, and hydrolyzing cyano to obtain temozolomide. The synthesis method of the novel intermediate provided by the invention is simple, the reaction of the novel intermediate and methylamine hydrochloride can effectively avoid the use of a highly toxic reagent methyl isocyanate and methylamino formyl chloride with higher toxicity and irritation, diazotization and ring-closure reaction are realized in one step, and the separation of unstable diazonium salt is avoided. The synthetic route is short, the yield is high, the reaction condition is mild, the process is stable, and the method is suitable for large-scale industrial production.
Owner:LUNAN PHARMA GROUP CORPORATION

Laminbutinyl bromooxamide derivatives with anticancer activity and composition thereof

ActiveCN107540569BExpand high value-added applicationsMaintain cationic propertiesOrganic compound preparationCarboxylic acid amides preparationSolventAniline
The invention discloses a laminine ester bromo oxamide derivative with anticancer activity and a composition thereof. The preparation method includes the steps of conducting backflow on laminine hydrochloride in thionyl chloride, adding methyl alcohol to conduct backflow again, steaming excess solvent, and regulating to neutral until white precipitate is dissolved out; filtering, using glacial alcohol and diethyl ether to wash, and conducting vacuum drying to obtain a white solid product; dissolving N-(5-bromine-2-hydroxyl aniline) ethyl oxalyl in an absolute ethyl alcohol solution, slowly adding drop by drop into anhydrous THF which dissolves prepared 6-N,N,N-trimethyl-2-carbamyl methylamine hydrochloride, conducting temperature reaction, and regulating the solution to neutral with dilutehydrochloric acid or a dilute hydrobromic acid solution until white precipitate is dissolved out; filtering, taking the precipitate to conduct recrystallization with ethyl alcohol, and conducting vacuum drying to obtain a target product. According to the laminine ester bromo oxamide derivative with anticancer activity and the composition thereof, through the introduction of a brominated ring structure, the cytotoxic activity of laminine to tumor cell strains in vitro can be enhanced.
Owner:QINGDAO UNIV

Preparation method of isavuconazonium sulfate intermediate

The invention discloses a preparation method of an isavuconazonium sulfate intermediate. The preparation method comprises the following steps: firstly, reacting absolute ethyl alcohol, sodium ethoxide and methylamine hydrochloride, cooling an obtained reaction solution, adding an ethanol solution of 1-chloroethyl methylcarbamate for continuous reaction, and conducting filtering to obtain an ethanol solution of methyl carbamic acid-1-chloroethyl ester; cooling the obtained solution, adding an ethanol solution of 2-chloro-3-pyridinemethanol for stirring reaction, filtering a reactant, removing ethanol, adding dichloromethane for dissolving, conducting washing after dissolving, and taking an organic phase, namely a dichloromethane solution of 1-chloro-ethyl (3-hydroxymethyl-pyridin-2-yl)-methylcarbamate; and firstly adding BOC-sarcosine into the obtained solution, then adding carbodiimide and 4-dimethylaminopyridine in batches for a reaction, and performing treatment after the reaction, so as to obtain the isavuconazole onium sulfate intermediate. The isavuconazonium sulfate is prepared by using the technical scheme of the invention, the side reaction of the process is less, and the purity of the obtained product is high.
Owner:KAIFENG MINGREN PHARMA

Preparation method of optically pure lobeline hydrochloride and enantiomer thereof

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of optically pure lobeline hydrochloride and an enantiomer of the optically pure lobeline hydrochloride. According to the method, benzoylacetic acid, methylamine hydrochloride and glutaraldehyde are used as raw materials, and a target product can be prepared through condensation, reduction, acylation, resolution, oxidation and hydrolysis reactions in sequence. According to the method, meso-racemic lobeline is derived into raceme through acylation by adopting a desymmetry strategy, so that conditions are created for further resolution, and the use of a chiral catalyst which is high in price and tedious in preparation is avoided. In the splitting step, the product is filtered, the obtained filtrate is subjected to hydrolysis and other treatments to obtain an intermediate compound II, and the intermediate compound II can be recycled, so that the process cost is greatly saved; and moreover, the whole preparation process flow is simple to operate, mild in condition, high in optical purity of the product and very suitable for large-scale industrial production.
Owner:GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products